The clinical utility of gene expression assays in breast cancer patients with 0-3 involved lymph nodes

被引：6
作者：
Barbi, Mali [2 ]
Makower, Della [1 ]
Sparano, Joseph A. [3 ]
机构：
[1] Montefiore Med Ctr, Dept Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷
关键词：
breast cancer; chemotherapy; gene expression profiling; hormone receptor-positive breast cancer; hormone therapy; 21-GENE RECURRENCE SCORE; ADJUVANT SYSTEMIC THERAPY; DISTANT RECURRENCE; POSTMENOPAUSAL PATIENTS; AMERICAN SOCIETY; GUIDE DECISIONS; PAM50; RISK; INDEX; PREDICTION; BENEFIT;
D O I：
10.1177/17588359211038467
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.
引用
收藏
页数：14
相关论文
共 55 条
  • [1] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
    Albain, Kathy S.
    Barlow, William E.
    Shak, Steven
    Hortobagyi, Gabriel N.
    Livingston, Robert B.
    Yeh, I-Tien
    Ravdin, Peter
    Bugarini, Roberto
    Boehner, Frederick L.
    Davidson, Nancy E.
    Sledge, George W.
    Winer, Eric P.
    Hudis, Clifford
    Ingle, James N.
    Perez, Edith A.
    Pritchard, Kathleen I.
    Shepherd, Lois
    Gralow, Julie R.
    Yoshizawa, Carl
    Allred, D. Craig
    Osborne, C. Kent
    Hayes, Daniel F.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
  • [2] Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
    Andre, Fabrice
    Ismaila, Nofisat
    Henry, N. Lynn
    Somerfield, Mark R.
    Bast, Robert C.
    Barlow, William
    Collyar, Deborah E.
    Hammond, M. Elizabeth
    Kuderer, Nicole M.
    Liu, Minetta C.
    Van Poznak, Catherine
    Wolff, Antonio C.
    Stearns, Vered
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (22) : 1956 - +
  • [3] [Anonymous], 2017, PROSIGNA ANNOTATED P
  • [4] [Anonymous], 2019, PROSIGNA BREAST CANC
  • [5] Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
    Bartlett, J. M. S.
    Sgroi, D. C.
    Treuner, K.
    Zhang, Y.
    Ahmed, I
    Piper, T.
    Salunga, R.
    Brachtel, E. F.
    Pirrie, S. J.
    Schnabel, C. A.
    Rea, D. W.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (11) : 1776 - 1783
  • [6] Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
    Bartlett, John M. S.
    Bayani, Jane
    Marshall, Andrea
    Dunn, Janet A.
    Campbell, Amy
    Cunningham, Carrie
    Sobol, Monika S.
    Hall, Peter S.
    Poole, Christopher J.
    Cameron, David A.
    Earl, Helena M.
    Rea, Daniel W.
    Macpherson, Iain R.
    Canney, Peter
    Francis, Adele
    McCabe, Christopher
    Pinder, Sarah E.
    Hughes-Davies, Luke
    Makris, Andreas
    Stein, Robert C.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (09):
  • [7] Equivalence of MammaPrint array types in clinical trials and diagnostics
    Beumer, Ines
    Witteveen, Anke
    Delahaye, Leonie
    Wehkamp, Diederik
    Snel, Mireille
    Dreezen, Christa
    Zheng, John
    Floore, Arno
    Brink, Guido
    Chan, Bob
    Linn, Sabine
    Bernards, Rene
    van 't Veer, Laura
    Glas, Annuska
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) : 279 - 287
  • [8] Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
    Blok, Erik J.
    Kroep, Judith R.
    Kranenbarg, Elma Meershoek-Klein
    Duijm-de Carpentier, Marjolijn
    Putter, Hein
    van den Bosch, Joan
    Maartense, Eduard
    van Leeuwen-Stok, A. Elise
    Liefers, Gerrit-Jan
    Nortier, Johan W. R.
    Rutgers, Emiel J. Th.
    van de Velde, Cornelis J. H.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01): : 40 - 48
  • [9] Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
    Buus, Richard
    Sestak, Ivana
    Kronenwett, Ralf
    Ferree, Sean
    Schnabel, Catherine A.
    Baehner, Frederick L.
    Mallon, Elizabeth A.
    Cuzick, Jack
    Dowsett, Mitch
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (02) : 126 - +
  • [10] Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Buyse, Marc
    Loi, Sherene
    van't Veer, Laura
    Viale, Giuseppe
    Delorenzi, Mauro
    Glas, Annuska M.
    d'Assignies, Mahasti Saghatchian
    Bergh, Jonas
    Lidereau, Rosette
    Ellis, Paul
    Harris, Adrian
    Bogaerts, Jan
    Therasse, Patrick
    Floore, Arno
    Amakrane, Mohamed
    Piette, Fanny
    Rutgers, Emiel
    Sotiriou, Christos
    Cardoso, Fatima
    Piccart, Martine J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1183 - 1192
123456